Loading market movers...

SINOVAC BIOTECH LTD

SVA

NASDAQBiotechnology🇺🇸North America

Drugs in Pipeline

19

Phase 3 Programs

15

Upcoming Catalysts

0

Next Catalyst

None scheduled

Drug Pipeline

Drug Name	Phase	Indication	Designations
bivalent enterovirus vaccine (Vero cell), inactivated	Phase 3	Hand, Foot, and Mouth Disease（HFMD)	-
investigational 23-valent PPV	Phase 3	Pneumococcal Infections	-
400U /0.5ml EV71 vaccine	Phase 3	Hand, Foot and Mouth Disease	-
Investigational sIPV	Phase 3	Poliomyelitis	-
three consecutive lots of EV71 vaccine	Phase 3	Hand, Foot and Mouth Disease	-
Three doses of experimental sIPV of lot 1 at the schedule of 2,3,4 months of age	Phase 3	Poliomyelitis	-
Quadrivalent influenza vaccine	Phase 3	Seasonal Influenza	-
Influenza Vaccine (Split Virion), Inactivated, Quadrivalent	Phase 3	Seasonal Influenza	-
Experimental vaccine	Phase 3	Poliomyelitis	-
Quadrivalent influenza vaccine(0.25ml)	Phase 3	Seasonal Influenza	-
36-71 months old children-experimental EV71 vaccine.	Phase 3	Hand, Foot and Mouth Disease	-
sIPV-sIPV-bOPV vaccination schedule	Phase 3	Poliomyelitis	-
Trivalent influenza vaccine (contains B/Victoria strain)	Phase 3	Seasonal Influenza	-
sIPV-bOPV-bOPV vaccination schedule	Phase 3	Poliomyelitis	-
Quadrivalent influenza vaccine(0.5ml)	Phase 3	Seasonal Influenza	-
Single-dose regimen of high dosage investigational sIPV	Phase 2	Poliomyelitis	-
100U EV71 vaccine with adjuvant	Phase 2	Infection, Viral, Enterovirus	-
split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14)	Phase 2	Influenza	-
pandemic influenza vaccine (H5N1 strain NIBRG-14)	Phase 2	Pandemic Influenza	-

Catalyst Timeline

0 upcoming, 0 past

No catalysts found.

Regulatory Approvals

SVA News